Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 27.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Chlorhexidine Gluconate (Sufrate SSD)® (Chlorhexidine Gluconate (Sufrate SSD)
Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine Gluconate (Sufrate SSD)® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Silver Sulfadiazine (Sufrate SSD) cream is indicated for the prevention and treatment of infection in severe burns. It is also been used in other skin conditions, such as leg ulcers, where infection may prevent healing and for the prophylaxis of infection in skin grafting. It has also been applied to the eyes in the treatment of superficial Aspergillus infections.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Sucralfate (Sufrate SSD) tablets, USP are indicated in:
Chlorhexidine Gluconate (Sufrate SSD) is a germicidal mouthwash that reduces bacteria in the mouth.
Chlorhexidine Gluconate (Sufrate SSD) oral rinse is used to treat gingivitis (swelling, redness, bleeding gums). Chlorhexidine Gluconate (Sufrate SSD) is usually prescribed by a dentist.
Chlorhexidine Gluconate (Sufrate SSD) oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Chlorhexidine Gluconate (Sufrate SSD) may also be used for purposes not listed in this medication guide.
Silver Sulfadiazine (Sufrate SSD) cream is used to prevent and treat wound infections in patients with second- and third-degree burns. Patients with severe burns or burns over a large area of the body must be treated in a hospital.
Silver Sulfadiazine (Sufrate SSD) is an antibiotic. It works by killing the bacteria or preventing its growth.
Silver Sulfadiazine (Sufrate SSD) is available only with your doctor's prescription.
Sucralfate (Sufrate SSD) is used to treat and prevent duodenal ulcers. Sucralfate (Sufrate SSD) may also be used for other conditions as determined by your doctor.
Sucralfate (Sufrate SSD) works by forming a ``barrier'' or ``coating'' over the ulcer. This protects the ulcer from the acid of the stomach, allowing it to heal. Sucralfate (Sufrate SSD) contains an aluminum salt.
Sucralfate (Sufrate SSD) is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Sucralfate (Sufrate SSD) is used in certain patients with the following medical conditions:
- Gastric ulcers
- Gastroesophageal reflux disease (a condition in which stomach acid washes back into the esophagus)
- Stomach or intestinal ulcers resulting from stress or trauma damage or from damage caused by medication used to treat rheumatoid arthritis
One Chlorhexidine Gluconate (Sufrate SSD) is inserted into a periodontal pocket with probing pocket depth (PD) 5 mm or greater. Up to 8 chips may be inserted in a single visit. Treatment is recommended to be administered once every three months in pockets with PD remaining 5 mm or greater. The periodontal pocket should be isolated and the surrounding area dried prior to chip insertion.
The Chlorhexidine Gluconate (Sufrate SSD) should be grasped using forceps (such that the rounded end points away from the forceps) and inserted into the periodontal pocket to its maximum depth. If necessary, the Chlorhexidine Gluconate (Sufrate SSD) can be further maneuvered into position using the tips of the forceps or a flat instrument. The Chlorhexidine Gluconate (Sufrate SSD) does not need to be removed since it biodegrades completely.
In the unlikely event of Chlorhexidine Gluconate (Sufrate SSD) dislodgement (in the two pivotal clinical trials, only 8 chips were reported lost), several actions are recommended, depending on the day of Chlorhexidine Gluconate (Sufrate SSD) loss. If dislodgement occurs 7 days or more after placement, the dentist should consider the subject to have received a full course of treatment. If dislodgement occurs within 48 hours after placement, a new Chlorhexidine Gluconate (Sufrate SSD) should be inserted. If dislodgement occurs more than 48 hours after placement, the dentist should not replace the Chlorhexidine Gluconate (Sufrate SSD), but reevaluate the patient at 3 months and insert a new Chlorhexidine Gluconate (Sufrate SSD) if the pocket depth has not been reduced to less than 5 mm.
How supplied
Chlorhexidine Gluconate (Sufrate SSD) (Chlorhexidine Gluconate (Sufrate SSD)) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC 52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack.
Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F).
Manufactured by: Dexcel® Pharma Technologies Ltd, HaMarpeh 7 St.,Jerusalem 91237, Israel. Distributed by: Adrian Pharmaceuticals, Spring Hill, Florida 34606. Iss. 01/10
Usual Adult Dose for Burns - External
Adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns: Apply to affected areas once or twice a day to a thickness of approximately 1/16 inch.
Whenever necessary, Silver Sulfadiazine (Sufrate SSD) topical should be reapplied to any areas from which it has been removed due to patient activity. The drug should be reapplied immediately after hydrotherapy.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Silver Sulfadiazine (Sufrate SSD) topical is contraindicated in pregnant women approaching or at term, premature infants, or newborn infants during the first 2 months of life, because the drug is known to increase the possibility of kernicterus.
There is potential cross sensitivity between Silver Sulfadiazine (Sufrate SSD) topical and other sulfonamides. If allergic reactions associated with Silver Sulfadiazine (Sufrate SSD) topical occur, therapy continuation should be weighed against the potential risks of the particular allergic reaction.
In some patients with glucose-6-phosphate dehydrogenase deficiency, the use of Silver Sulfadiazine (Sufrate SSD) topical may be hazardous, as hemolysis may occur.
If renal and hepatic functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of Silver Sulfadiazine (Sufrate SSD) topical should be weighed against the therapeutic benefit being achieved.
Serum sulfa concentrations may approach adult therapeutic levels during the treatment of burn wounds involving extensive areas of the body. Therefore, sulfa concentrations should be monitored in these patients. Renal function should be closely monitored and the urine should be checked for sulfa crystals.
Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.
Of the total number of patients in clinical studies of Silver Sulfadiazine (Sufrate SSD) topical, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
Prompt institution of appropriate regimens for care of the burned patient is of major importance and includes the control of shock and pain.
Burn wounds should be cleansed and debrided before administration of the drug. Silver Sulfadiazine (Sufrate SSD) topical should be applied under sterile conditions. The burn areas should be covered with Silver Sulfadiazine (Sufrate SSD) topical at all times. Dressings are not required; however, if individual patient requirements make dressings necessary, they may be used.
Treatment should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be removed from the therapeutic regimen while the chance of infection remains unless a significant adverse reaction occurs.
Usual Adult Dose for Duodenal Ulcer
1 g orally on an empty stomach 4 times a day or alternatively,
2 g orally on an empty stomach 2 times a day.
Usual Adult Dose for Duodenal Ulcer Prophylaxis
1 g orally on an empty stomach twice a day.
Usual Adult Dose for Gastric Ulcer
1 g orally on an empty stomach 4 times a day.
Usual Adult Dose for Gastroesophageal Reflux Disease
1 g orally on an empty stomach 4 times a day.
Usual Adult Dose for Stress Ulcer Prophylaxis
1 g orally on an empty stomach every 4 to 6 hours.
Usual Adult Dose for Stomatitis
1 g (10 mL) topically as a suspension 4 times a day.
Usual Adult Dose for Hyperphosphatemia of Renal Failure
1 g orally on an empty stomach twice a day.
This dose may be titrated based on serum phosphate levels.
Usual Pediatric Dose for Stomatitis
Safety and effectiveness of Sucralfate (Sufrate SSD) in pediatric patients have not been established. However, the use of Sucralfate (Sufrate SSD) may be appropriate in some situations.
Greater than 1 year: 250 to 500 mg (2.5 to 5 mL) topically as a suspension 4 times a day for treatment of stomatitis.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
While short-term therapy with Sucralfate (Sufrate SSD) can result in complete healing of a duodenal ulcer, a successful course of treatment with Sucralfate (Sufrate SSD) should not be expected to alter the posthealing frequency or severity of duodenal ulceration.
When Sucralfate (Sufrate SSD) is given orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of Sucralfate (Sufrate SSD) with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of Sucralfate (Sufrate SSD) and concomitant medications adequately excrete aluminum in the urine. Patients receiving dialysis or those with chronic renal failure have impaired excretion of absorbed aluminum. Further, aluminum does not cross dialysis membranes because it is bound to albumin and transferring plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Sucralfate (Sufrate SSD) should be used with caution in patients with chronic renal failure.
In general, dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sucralfate (Sufrate SSD) is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because the elderly are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Dialysis
Data not available
Other Comments
Therapy should be continued approximately 4 to 8 weeks depending on disease and severity.
See also:
What is the most important information I should know about Chlorhexidine Gluconate (Sufrate SSD)?
You should not use this medication if you are allergic to Chlorhexidine Gluconate (Sufrate SSD).
If you have periodontal disease, you may need special treatments while you are using Chlorhexidine Gluconate (Sufrate SSD).
Chlorhexidine Gluconate (Sufrate SSD) oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Do not give this medication to a child or teenager without a doctor's advice.
Do not add water to Chlorhexidine Gluconate (Sufrate SSD) oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Sufrate SSD).
Avoid eating, drinking, or brushing your teeth just after using this medication.
Do not use any other mouthwash unless your doctor has told you to.
Chlorhexidine Gluconate (Sufrate SSD) can stain teeth, dentures, tooth restorations, your tongue, or the inside of your mouth. Talk with your dentist about ways to remove staining from these surfaces. Stains may be harder to remove from false teeth that have scratches in their surfaces.
Visit your dentist at least every 6 months for preventive tooth and gum care.
See also:
What is the most important information I should know about Silver Sulfadiazine (Sufrate SSD)?
Silver Sulfadiazine (Sufrate SSD) Cream, USP 1% is contraindicated in patients who are hypersensitive to Silver Sulfadiazine (Sufrate SSD) or any of the other ingredients in the preparation.
Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine (Sufrate SSD) Cream, USP 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.
See also:
What is the most important information I should know about Sucralfate (Sufrate SSD)?
Before taking Sucralfate (Sufrate SSD), tell your doctor if you have diabetes, kidney disease, or if you are on dialysis.
Take Sucralfate (Sufrate SSD) on an empty stomach, at least 1 hour before or 2 hours after a meal.
Take this medicine for the full prescribed length of time. Your symptoms may improve before the ulcer is completely healed.
Avoid taking any other medications within 2 hours before or after you take Sucralfate (Sufrate SSD). Sucralfate (Sufrate SSD) can make it harder for your body to absorb other medications you take by mouth.
Avoid using antacids without your doctor's advice. Use only the type of antacid your doctor recommends. Some antacids can make it harder for Sucralfate (Sufrate SSD) to work in your stomach. If your doctor does recommend using an antacid, avoid taking it within 30 minutes before or after taking Sucralfate (Sufrate SSD).
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Rinse your mouth with Chlorhexidine Gluconate (Sufrate SSD) twice daily after brushing your teeth.
Measure your dose using the cup provided with the medication. Swish the medicine in your mouth for at least 30 seconds, then spit it out. Do not swallow the mouthwash.
Do not add water to the oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Sufrate SSD).
Chlorhexidine Gluconate (Sufrate SSD) may leave an unpleasant taste in your mouth. Do not rinse your mouth to remove this taste after using the medication. You may rinse the medicine away and reduce its effectiveness.
Use this medication for the full prescribed length of time. Your symptoms may improve before your gingivitis is completely cleared. Chlorhexidine Gluconate (Sufrate SSD) will not treat a viral or fungal infection such as cold sores, canker sores, or oral thrush (yeast infection).
Visit your dentist at least every 6 months for preventive tooth and gum care.
Store Chlorhexidine Gluconate (Sufrate SSD) at room temperature away from moisture and heat.
Use Silver Sulfadiazine (Sufrate SSD) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash your hands well before and after you apply Silver Sulfadiazine (Sufrate SSD). Use a sterile-gloved hand to apply Silver Sulfadiazine (Sufrate SSD) to a thickness of approximately 1/16 inch on all affected areas. Whenever necessary, reapply the cream to keep the affected areas covered at all times.
- Dressings are usually not required with Silver Sulfadiazine (Sufrate SSD). However, follow your doctor's instructions if a dressing is needed.
- Follow the directions provided by your doctor for bathing or washing the affected area.
- To prevent or to clear up your infection completely, continue using Silver Sulfadiazine (Sufrate SSD) for the full course of treatment even if your condition improves in a few days. Do not miss any doses.
- If you miss a dose of Silver Sulfadiazine (Sufrate SSD), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Silver Sulfadiazine (Sufrate SSD).
Use Sucralfate (Sufrate SSD) suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Sucralfate (Sufrate SSD) suspension by mouth on an empty stomach at least 1 hour before or 2 hours after eating.
- Shake well before each use.
- Use a measuring device marked for medicine dosing. If you are unsure of how to measure your dose, ask your doctor or pharmacist for help.
- Sucralfate (Sufrate SSD) suspension should only be taken by mouth. Do NOT inject Sucralfate (Sufrate SSD) suspension.
- Do not take an antacid for at least 30 minutes before or after taking Sucralfate (Sufrate SSD) suspension.
- It may take 4 to 8 weeks for complete healing of your ulcer. Continue taking Sucralfate (Sufrate SSD) suspension for the full course of treatment even if you feel better.
- Do not take Sucralfate (Sufrate SSD) suspension at the same time as other medicines. Take Sucralfate (Sufrate SSD) suspension at least 2 hours after other medicines. If you are not sure about the best time to take Sucralfate (Sufrate SSD) suspension, ask your doctor or pharmacist.
- If you miss a dose of Sucralfate (Sufrate SSD) suspension, take it as soon as possible. If it is almost time for your next dose, go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Sucralfate (Sufrate SSD) suspension.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled Indications
Gingivitis:
Oral rinse: Antimicrobial dental rinse for gingivitis treatment
Periodontitis: Periodontal chip: Adjunctive therapy to scaling and root planning procedures to reduce pocket depth in patients with periodontitis
Off Label Uses
Medication-related osteonecrosis of the jaw (MRONJ), adjunctive therapy:
Oral rinse:
Based on a position paper by the American Association of Maxillofacial Surgeons (AAOMS), Chlorhexidine Gluconate (Sufrate SSD) oral rinse is an effective and recommended adjunctive treatment strategy in the management of medication-related osteonecrosis of the jaw (MRONJ) (stage 1 and above [eg, patients with exposed and necrotic bone or fistulae that probes to bone]).
Oropharyngeal decontamination to reduce the risk of ventilator-associated or hospital-acquired pneumonia, Cardiac surgical patients:
Oral rinse:
Data from a prospective, randomized, double-blind, placebo-control trial and a prospective, randomized, case-controlled trial in patients undergoing coronary artery bypass grafting, valve, or other open heart surgical procedures who received Chlorhexidine Gluconate (Sufrate SSD) 0.12% oral rinse during the perioperative period showed a decreased rate in hospital-acquired pneumonia. However, the trials used in both meta-analyses were heterogeneous and included patients in a variety of settings (eg, cardiothoracic, general ICU, mixed medical-surgical ICU, trauma ICU). The trials also displayed significant variability with Chlorhexidine Gluconate (Sufrate SSD) treatment regimens. Chlorhexidine Gluconate (Sufrate SSD) concentration varied from 0.12%, 0.2%, or 2% across studies. Frequency of administration, Chlorhexidine Gluconate (Sufrate SSD) dosage form (oral rinse, gel, paste, foam), and technique of application also varied across studies. In the US, Chlorhexidine Gluconate (Sufrate SSD) for use in the oral cavity is commercially available only as 0.12% solution. Additional trials may be necessary to further define the role of Chlorhexidine Gluconate (Sufrate SSD) oral rinse in this condition.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Silver Sulfadiazine (Sufrate SSD) is a topical antimicrobial agent used as an adjunct to prevent and treat infection of burns.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Sucralfate (Sufrate SSD) is used to treat stomach ulcers, bowel ulcers and inflammation of the stomach.
See also:
What other drugs will affect Chlorhexidine Gluconate (Sufrate SSD)?
Chlorhexidine Gluconate (Sufrate SSD) is incompatible with the soap, and detergents containing anionic group (saponins, sodium lauryl sulfate, sodium carboxymethyl cellulose).
Chlorhexidine Gluconate (Sufrate SSD) Pharmaniaga is compatible with any medication containing cationic group (cetrimonium bromide, benzalkonium chloride).
Potentiates antidiabetic effect of sulphonylureas. Not antagonised by PABA.
See also:
What other drugs will affect Sucralfate (Sufrate SSD)?
Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination
Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification
Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification
Cholic Acid: Sucralfate (Sufrate SSD) may decrease the absorption of Cholic Acid. Consider therapy modification
Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification
Digoxin: Sucralfate (Sufrate SSD) may decrease the serum concentration of Digoxin. Specifically, Sucralfate (Sufrate SSD) may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before Sucralfate (Sufrate SSD). Consider therapy modification
Dolutegravir: Sucralfate (Sufrate SSD) may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after Sucralfate (Sufrate SSD). Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after Sucralfate (Sufrate SSD). Consider therapy modification
Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification
Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification
Furosemide: Sucralfate (Sufrate SSD) may decrease the serum concentration of Furosemide. Sucralfate (Sufrate SSD) may impair the absorption of furosemide. Management: Avoid concomitant oral administration of furosemide and Sucralfate (Sufrate SSD). Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide. Consider therapy modification
Ketoconazole (Systemic): Sucralfate (Sufrate SSD) may decrease the serum concentration of Ketoconazole (Systemic). Monitor therapy
Levothyroxine: Sucralfate (Sufrate SSD) may decrease the serum concentration of Levothyroxine. Monitor therapy
Multivitamins/Fluoride (with ADE): May increase the serum concentration of Sucralfate (Sufrate SSD). Specifically, the absorption of aluminum may be increased. Sucralfate (Sufrate SSD) may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, Sucralfate (Sufrate SSD) may impair the absorption of fluoride. Management: Avoid administration of aluminum-containing products, such as Sucralfate (Sufrate SSD), within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination altogether. Consider therapy modification
Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Sucralfate (Sufrate SSD). Specifically, the absorption of aluminum from Sucralfate (Sufrate SSD) may be increased, leading to an increase in the serum aluminum concentration. Avoid combination
PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification
Phosphate Supplements: Sucralfate (Sufrate SSD) may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 2 hours before Sucralfate (Sufrate SSD) may reduce the significance of the interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Consider therapy modification
QuiNIDine: Sucralfate (Sufrate SSD) may decrease the serum concentration of QuiNIDine. Specifically, Sucralfate (Sufrate SSD) may decrease the absorption of quinidine. Management: Administer quinidine at least 2 hours before Sucralfate (Sufrate SSD). Consider therapy modification
Quinolones: Sucralfate (Sufrate SSD) may decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and Sucralfate (Sufrate SSD) to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone. Exceptions: LevoFLOXacin (Oral Inhalation). Consider therapy modification
Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Consider therapy modification
Sulpiride: Sucralfate (Sufrate SSD) may decrease the serum concentration of Sulpiride. Management: Separate administration of Sucralfate (Sufrate SSD) and sulpiride by at least 2 hours in order to minimize the impact of Sucralfate (Sufrate SSD) on sulpiride absorption. Consider therapy modification
Tetracyclines: Sucralfate (Sufrate SSD) may decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to Sucralfate (Sufrate SSD) in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to Sucralfate (Sufrate SSD). Exceptions: Eravacycline. Consider therapy modification
Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification
Vitamin D Analogs: May increase the serum concentration of Sucralfate (Sufrate SSD). Specifically, the absorption of aluminum from Sucralfate (Sufrate SSD) may be increased, leading to an increase in the serum aluminum concentration. Avoid combination
Vitamin K Antagonists (eg, warfarin): Sucralfate (Sufrate SSD) may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate (Sufrate SSD) may decrease the serum concentration of Vitamin K Antagonists. Specifically, Sucralfate (Sufrate SSD) may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before Sucralfate (Sufrate SSD). Consider therapy modification
See also:
What are the possible side effects of Chlorhexidine Gluconate (Sufrate SSD)?
The most common side effects associated with Chlorhexidine Gluconate (Sufrate SSD) oral rinses are (1) an increase in staining of teeth and other oral surfaces, (2) an increase in calculus formation; and (3) an alteration in taste perception; see WARNINGS and PRECAUTIONS.
Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with the use of Chlorhexidine Gluconate (Sufrate SSD) rinse.
The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%.
Among post marketing reports, the most frequently reported oral mucosal symptoms associated with Chlorhexidine Gluconate (Sufrate SSD) oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.
Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using Chlorhexidine Gluconate (Sufrate SSD) oral rinse.
There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using Chlorhexidine Gluconate (Sufrate SSD) oral rinse.
See also:
What are the possible side effects of Silver Sulfadiazine (Sufrate SSD)?
Applies to Silver Sulfadiazine (Sufrate SSD) topical: topical cream
As well as its needed effects, Silver Sulfadiazine (Sufrate SSD) topical may cause unwanted side effects that require medical attention.
Severity: Moderate
If any of the following side effects occur while taking Silver Sulfadiazine (Sufrate SSD) topical, check with your doctor or nurse as soon as possible:
Incidence not known:
- Back, leg, or stomach pains
- blistering, peeling, or loosening of the skin
- blue-green to black skin discoloration
- dark urine
- fever with or without chills
- general body swelling
- increased sensitivity of the skin to sunlight, especially in patients with burns on large areas
- intense itching of burn wounds
- light-colored stools
- lower back or side pain
- nausea or vomiting
- pinpoint red spots on the skin
- red skin lesions, often with a purple center
- red, swollen skin
- skin rash
- sores, ulcers, or white spots in the mouth or on the lips
- swollen or painful glands
- unusual bleeding or bruising
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- yellow eyes and skin
Minor Side Effects
Some Silver Sulfadiazine (Sufrate SSD) topical side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Incidence not known:
- Brownish-gray skin discoloration
- burning feeling on treated areas
See also:
What are the possible side effects of Sucralfate (Sufrate SSD)?
Adverse reactions to Sucralfate (Sufrate SSD) tablets in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with Sucralfate (Sufrate SSD), adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:
Gastrointestinal: diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomiting.
Dermatological: pruritus, rash
Nervous System: dizziness, insomnia, sleepiness, vertigo
Other: back pain, headache
Postmarketing reports of hypersensitivity reactions, including urticaria (hives), angioedema, respiratory difficulty, rhinitis, laryngospasm, and facial swelling have been reported in patients receiving Sucralfate (Sufrate SSD) tablets. Similar events were reported with Sucralfate (Sufrate SSD) Suspension. However, a causal relationship has not been established. Cases of hyperglycemia have been reported with Sucralfate (Sufrate SSD).
Bezoars have been reported in patients treated with Sucralfate (Sufrate SSD). The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings.
Inadvertent injection of insoluble Sucralfate (Sufrate SSD) and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate (Sufrate SSD) is not intended for intravenous administration.
Each chip contains Chlorhexidine Gluconate (Sufrate SSD) 2.5 mg in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde).
Chlorhexidine Gluconate (Sufrate SSD) also contains glycerin and purified water as excipients.
Chlorhexidine Gluconate (Sufrate SSD), an antimicrobial agent, is 1, 1'-hexamethylenebis [5-(p-chlorophenyl)biguanide] di-D-gluconate. Molecular Formula: C22H30Cl2N10·2C6H12O7. Molecular Weight: 897.8.
Silver Sulfadiazine (Sufrate SSD) is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns. [Wikipedia]
Each tablet contains 1g of Sucralfate (Sufrate SSD).
Sucralfate (Sufrate SSD) (Sucralfate (Sufrate SSD)) is a white, amorphous powder which is soluble in strong acids and alkalis but practically insoluble in water and in alcohol. It is a basic, aluminum complex of sucrose octasulfate.
Sucralfate (Sufrate SSD) is α-D-glucopyranoside, β-D-fructofuranosyl, octakis (hydrogen sulfate), aluminum complex. Its molecular formula is C12HmAl16OnS8 (m and n are approximately 54 and 75, respectively, resulting in an average molecular weight of about 2086 daltons).